

## **Nouveau Biosciences and Ardena Enter Agreement to Make Clinical Grade Kromastat, an Innovative Nanomedicine for Early Phase Studies**

[New York, NY – January 5, 2026] Nouveau Biosciences, a biotechnology company pioneering new approaches to discover novel targeted nanomedicines to improve cancer therapeutics, today announced that it has entered into an agreement with Ardena to manufacture their lead asset Kromastat (previously known as NBS-M001).

Ardena is a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies. Its expertise spans small molecule API manufacturing to development and accelerated manufacturing. Importantly, Ardena has an entire division dedicated to the synthesis, conjugation and production of nanomedicines, including Annex 1 compliant GMP manufacturing and the bioanalytical services required to advance the development of this new innovative class of drugs.

Jeremie Trochu, Chief Executive Officer of Ardena said, “We are honored to partner with Nouveau Biosciences as they progress their lead asset to the clinic. We have been truly impressed by the company’s vision, passion, deep technical expertise, and the impressive track-record of their leadership over decades. We really look forward to supporting Owen and Joe in their new venture and help Nouveau achieve its mission to transform cancer care.”

“We are thrilled to begin this journey with Ardena” said Owen A. O’Connor, M.D., Ph.D., Chief Executive Officer and Chairman of Nouveau Biosciences. “Their state-of-the-art nanomedicine facility in the Netherlands, and their deep technical expertise across the entire space of nanotherapeutics is probably the most sophisticated and seamlessly integrated of any I have seen to date. This collaboration represents an extremely critical step for Nouveau, not just with our lead asset, but for our rapidly evolving pipeline as well.”

Nouveau Biosciences has developed a proprietary drug discovery technology coupled to a polymer-based nanochemistry capability that enhances drug targeting, tolerability and efficacy. The platform enables the creation of novel anti-cancer agents with strong IP, drugs that are now emerging as first-in-class and best-in-disease. With a clinic-ready lead asset built on validated chemistry and biology, the company is positioned to generate a pipeline of de-risked, IP-protected candidates.

## **About Nouveau Biosciences**

*Nouveau Biosciences* is an innovative biotechnology company that deploys a proprietary platform technology that integrates the latest scientific advances in cancer biology, genomics, computational biology and nanomedicine to produce precision targeted drugs tailored for very specific types of cancer. Its polymer-based nanoparticles are engineered to deliver both individual drugs and optimized combinations with enhanced precision, leading to improved tolerability and efficacy. The company's lead program is clinic-ready, backed by strong intellectual property, and designed to address high-need oncology indications. The technology represents a quantum advance in the generation of highly precision targeted drugs, offering innumerable advances over technologies.

## **About Ardena**

Ardena is a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) enabling precision medicines and other complex therapies. Its integrated solutions enable innovative and complex molecules through services in nanomedicine, drug product and substance manufacturing, solid-state chemistry, bioanalytical services, and CMC regulatory support. Ardena's nanomedicine capabilities cover the formulation, process development, and GMP manufacturing of advanced delivery systems including lipid, polymeric, and metal nanoparticles.

## **Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the companies' future plans, development and licensing of cancer therapeutics, and the potential success of the collaboration. All statements other than statements of historical fact are forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. Nouveau Biosciences undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by law.

## **Media Contact**

Petrina Whyte

[media@nouveaubiosciences.com](mailto:media@nouveaubiosciences.com)